Free Trial

Sunbeam Capital Management LLC Invests $613,000 in Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. logo with Medical background

Sunbeam Capital Management LLC acquired a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 6,166 shares of the company's stock, valued at approximately $613,000.

Several other institutional investors have also recently modified their holdings of MRK. Midwest Capital Advisors LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $26,000. Financial Life Planners acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $28,000. Noble Wealth Management PBC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $28,000. Halbert Hargrove Global Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $28,000. Finally, Promus Capital LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $30,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Down 0.1%

Shares of NYSE MRK traded down $0.08 during midday trading on Tuesday, reaching $77.50. 11,867,802 shares of the company's stock were exchanged, compared to its average volume of 12,568,652. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $134.63. The stock has a market capitalization of $194.60 billion, a PE ratio of 11.52, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. The business's fifty day moving average price is $81.43 and its two-hundred day moving average price is $91.15.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.06. The firm had revenue of $15.53 billion during the quarter, compared to analyst estimates of $15.59 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. Merck & Co., Inc.'s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.07 earnings per share. Analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. declared that its Board of Directors has approved a share buyback plan on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to purchase up to 4.1% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's leadership believes its stock is undervalued.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 8th. Shareholders of record on Monday, June 16th will be paid a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a yield of 4.18%. Merck & Co., Inc.'s payout ratio is currently 47.16%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, SVP Dalton E. Smart III sold 4,262 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $82.76, for a total value of $352,723.12. Following the completion of the transaction, the senior vice president now directly owns 7,778 shares in the company, valued at $643,707.28. The trade was a 35.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Citigroup restated a "neutral" rating and issued a $84.00 target price (down previously from $115.00) on shares of Merck & Co., Inc. in a research report on Wednesday, May 14th. Guggenheim restated a "buy" rating and set a $115.00 price target on shares of Merck & Co., Inc. in a report on Thursday, April 17th. TD Securities cut Merck & Co., Inc. from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $121.00 to $100.00 in a research report on Monday, February 10th. Cantor Fitzgerald downgraded Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research note on Tuesday, May 20th. Finally, Bank of America cut their target price on Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating for the company in a research note on Wednesday, February 5th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $109.19.

Read Our Latest Research Report on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines